Funding supports efforts by National Organization for Rare Disorders (NORDⓇ) and Global Genes to address needs of the rare disease community arising from COVID-19 pandemic
BOSTON, June 24, 2020 /3BL Media/ -- The Alexion Charitable Foundation, launched by Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in February 2020, has announced it has awarded a total of $1.1 million in initial grants that align with its Rare Belonging® focus. Rare Belonging seeks to advance emotional well-being and educational opportunities, and provide relief for critical needs, for those living with or affected by a rare disease.
Alexion’s vision is to continuously raise the bar to deliver on patient expectations with solutions designed for them as people – meaning we want to take the time to understand their social and emotional lives, as well as their medical condition.
In the world of rare diseases, where so many conditions remain undiagnosed and untreated, we take seriously the opportunity to really listen to and learn from patients and caregivers and their healthcare providers. At Alexion, innovation includes really focusing our collective efforts to strive toward understanding patients’ needs, including meaningful therapies and beyond. We are focused on innovating in all we do to improve the day-to-day experience of people living with a rare disease.
For hundreds of thousands of children living with serious illnesses and their families around the world, a serious illness can disrupt their childhood and add strain to families. But for those children living with rare diseases and their families, the experience can be even more challenging and isolating. That’s where camp comes in.
SeriousFun Children’s Network, founded by actor and philanthropist Paul Newman, provides fun, life-changing camp experiences to children living with serious illnesses and their families throughout the world—totally free of charge. These medically safe, inclusive experiences allow campers to connect with peers and build confidence, empowering them to value the possibility and potential of their lives beyond camp—and beyond their illnesses.
At Shire, supporting patients is at the heart of being a champion for patients. Beyond discovering and developing medicines, we are committed to dramatically shortening the time to diagnosis for rare diseases, and we aim to support patients along the entire patient journey, from conducting clinical trials to enabling patients to better manage their care through the use of innovative digital technologies, and beyond.
BETHESDA, MD – April 27, 2018 /3BL Media/ -- Four recipients of the Shire/ACMG Foundation Next Generation Fellowship Awards were announced during the American College of MedicalGenetics and Genomics (ACMG) 2018 Annual Clinical Genetics Meeting in Charlotte, NorthCarolina. The four awards were the second set of awards given after Shire made a $1.65million commitment in 2017 to support the training of future medical geneticists.
CAMBRIDGE, Mass., March 22, 2018 /3BL Media/ – Shire plc (LSE: SHP, NASDAQ: SHPG) today announced the release of the Company’s 2017 Annual Responsibility Review. The Review, available at shire.com/responsibility outlines Shire’s new Responsibility strategy that includes ambitious long-term goals to be achieved by 2025, aimed at further enhancing the Company’s commitment to Responsibility and positively impacting patients, our employees, and our communities.
In February of 2016, we committed $3 million over three years to SeriousFun Children’s Network. Our support will enable nearly 1,000 children, many with rare diseases, to attend SeriousFun’s transformative camps and programs free of charge. This is a look at our partnership in year two!
Our volunteers had this to say (and more) in the video above:
"What I experienced at camp was beyond my expectations."
"Every camper was made to feel that FUN was the most important goal (of the day)."
"The campers attitudes and strength were absolutely contagious."
Shire is the global leader in serving patients with rare diseases. We strive to develop innovative therapies across a core of rare disease areas, supplemented by diversified capabilities in highly specialized conditions. We feel a strong sense of urgency to address the high unmet medical needs of these patient communities.